ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Biogen Phase 1

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Aug 30, 2021 12:48am

127 Views

Post# 33780453

RE:Biogen Phase 1

Thanks TB. Given the slightly more competitive landscape these days, I'd be good with a meager $10B, lol. Hopefully PMN's idea to collect biomarker data during Phase I could support the best-in-class hypothesis and chum the waters. Just demonstrating fewer ARIA E side effects at much higher doses would also be a big selling point. Exciting times ahead.

<< Previous

Bullboard Posts

Next >>

Mastering options Greeks: Essential knowledge for informed trading